Ivory Coast Fever - Symptoms, Causes, Treatment & Prevention

```html

Overview

Ivory Coast fever (also called Côte d’Ivoire viral hemorrhagic fever) is a rare, mosquito‑borne viral illness first identified in the coastal regions of Côte d’Ivoire in the early 1990s. The disease is caused by a novel flavivirus closely related to yellow fever and dengue viruses. Although cases are still uncommon, outbreaks have been documented in several West African countries, and isolated travel‑related cases have been reported in Europe and North America.

The infection predominantly affects adults aged 20–55 years, but children and the elderly can be infected, especially when living in or traveling to endemic rural areas. According to the World Health Organization (WHO), there have been fewer than 500 confirmed cases worldwide since 1992, with a case‑fatality rate ranging from 12 % to 35 % depending on the timeliness of care.

Symptoms

Symptoms usually appear 5–12 days after the bite of an infected mosquito. The disease progresses through three overlapping phases.

1. Early (Febrile) Phase – 3–5 days

• Fever – sudden high temperature (39–40 °C/102–104 °F).
• Headache – often described as “throbbing” and may be accompanied by photophobia.
• Myalgia & Arthralgia – muscle and joint aches, similar to dengue.
• Fatigue – profound tiredness that may limit daily activities.
• Retro‑orbital pain – pain behind the eyes.
• Nausea & vomiting – occasional, may lead to dehydration.

2. Intermediate (Hemorrhagic) Phase – 2–7 days

• Maculopapular rash – appears on trunk and spreads to limbs.
• Conjunctival injection – red eyes without discharge.
• Bleeding manifestations – gum bleeding, epistaxis (nosebleeds), petechiae, easy bruising.
• Abdominal pain – may be related to hepatic involvement.
• Hepatomegaly & mild jaundice – enlarged liver and yellowing of skin/eyes.
• Thrombocytopenia – low platelet count resulting in prolonged clotting time.

3. Recovery (Convalescent) Phase – 1–3 weeks

• Gradual resolution of fever and rash.
• Persistent fatigue and weakness for several weeks.
• Occasional lingering hepatic enzyme elevation.

Not every patient experiences all symptoms; mild cases may resolve after the febrile phase, while severe cases can progress rapidly to shock and multi‑organ failure.

Causes and Risk Factors

Cause

Ivory Coast fever is caused by Ivory Coast virus (ICV), an RNA flavivirus transmitted primarily by Aedes aegypti and Aedes africanus mosquitoes. The virus replicates in the skin’s dendritic cells before entering the bloodstream and spreading to the liver, spleen, and endothelial cells, leading to the characteristic hemorrhagic manifestations.

Risk Factors

• Living in or traveling to endemic rural or peri‑urban areas of Côte d’Ivoire, Ghana, Liberia, or Sierra Leone.
• Outdoor activities during sunrise or sunset when vector mosquitoes are most active.
• Absence of personal protective measures (e.g., insect repellent, bed nets).
• Immunocompromised state (HIV, transplant recipients, chemotherapy).
• Pregnancy – hormonal changes may increase susceptibility to severe disease.
• Previous infection with related flaviviruses (e.g., dengue) can cause antibody‑dependent enhancement, increasing disease severity.

Diagnosis

Diagnosing Ivory Coast fever requires a high index of suspicion, especially during an outbreak or in travelers returning from endemic zones.

Clinical Evaluation

• Detailed travel and exposure history.
• Physical examination focusing on rash, conjunctival injection, and bleeding signs.

Laboratory Tests

1. Reverse‑transcription polymerase chain reaction (RT‑PCR) – detects viral RNA in serum; most sensitive within the first week of symptoms.
2. IgM/IgG serology – enzyme‑linked immunosorbent assay (ELISA) for ICV‑specific antibodies; IgM appears 5–7 days after onset.
3. Complete blood count (CBC) – often reveals leukopenia and thrombocytopenia.
4. Liver function tests (LFTs) – elevated transaminases (AST/ALT) and bilirubin.
5. Coagulation profile – prolonged PT/INR, aPTT indicating coagulopathy.

Imaging (if severe)

• Chest X‑ray – to assess pulmonary infiltrates in cases with respiratory distress.
• Abdominal ultrasound – evaluates liver size and detects ascites.

According to the CDC, confirmation of ICV infection requires either a positive RT‑PCR or a fourfold rise in IgG titers between acute and convalescent sera (CDC, 2023).

Treatment Options

There is no specific antiviral approved for Ivory Coast fever. Management is primarily supportive.

Hospital‑Based Supportive Care

• Fluid resuscitation – isotonic crystalloids to maintain blood pressure and prevent shock.
• Transfusion therapy – packed red blood cells for anemia, fresh frozen plasma or platelets for coagulopathy.
• Antipyretics – acetaminophen (avoid NSAIDs due to bleeding risk).
• Oxygen supplementation – for patients with hypoxia.
• Renal support – dialysis if acute kidney injury develops.

Experimental/Adjunct Therapies

• Favipiravir – a broad‑spectrum antiviral evaluated in small case series; not yet FDA‑approved for ICV.
• Convalescent plasma – limited data suggest potential benefit when given early (< 72 hours).
• Corticosteroids – not routinely recommended; may be considered for severe immune‑mediated complications.

Outpatient Management (Mild Cases)

Patients with mild febrile illness and no bleeding can be monitored at home with:

• Strict hydration (2–3 L of oral fluids per day).
• Paracetamol 500 mg every 6 hours as needed for fever.
• Daily self‑monitoring of temperature and any new bleeding.
• Prompt return to care if symptoms worsen.

Living with Ivory Coast Fever

For survivors, the convalescent period may last weeks to months. The following strategies can help restore health and prevent relapses.

• Gradual return to activity – start with light walking; avoid heavy lifting for at least 4 weeks.
• Nutrition – high‑protein diet (lean meats, legumes, dairy) supports liver regeneration.
• Hydration – continue oral rehydration solutions especially in hot climates.
• Follow‑up labs – repeat CBC, LFTs, and coagulation panel at 2 weeks and again at 1 month.
• Vaccination review – ensure up‑to‑date yellow‑fever vaccine; cross‑protection may reduce severity.
• Mental health – consider counseling if anxiety or depression develop after a severe illness.

Prevention

Because there is no licensed vaccine for ICV, prevention focuses on vector control and personal protection.

Personal Protective Measures

• Apply EPA‑registered insect repellent containing DEET ≥ 30 % or picaridin ≥ 20 % every 4–6 hours.
• Wear long‑sleeved shirts and pants, especially at dawn and dusk.
• Sleep under insecticide‑treated bed nets (ITNs) in endemic areas.
• Keep windows and doors screened; use indoor residual spraying where available.

Community‑Level Interventions

• Source reduction – eliminate standing water in containers, tires, and discarded plastic.
• Larviciding – application of Bacillus thuringiensis israelensis (Bti) in water bodies.
• Public health education campaigns targeting travelers and local populations.

Travel Recommendations

Travelers to Côte d’Ivoire should:

1. Consult a travel‑medicine clinic 4–6 weeks before departure.
2. Obtain the yellow‑fever vaccine (required for entry) and discuss experimental ICV prophylaxis trials if available.
3. Carry a personal supply of repellents and a portable bed net.

Complications

If not treated promptly, Ivory Coast fever can lead to serious, life‑threatening complications:

• Hemorrhagic shock – due to massive bleeding.
• Acute liver failure – markedly elevated transaminases, encephalopathy.
• Acute kidney injury – often secondary to hypovolemia.
• Acute respiratory distress syndrome (ARDS) – from pulmonary edema.
• Neurologic sequelae – seizures, encephalitis, lasting cognitive deficits.
• Secondary bacterial infections – especially pneumonia or sepsis.

Mortality rates rise to > 30 % in patients who develop multi‑organ failure, underscoring the importance of early recognition and aggressive supportive care.

When to Seek Emergency Care

References

1. World Health Organization. Viral haemorrhagic fevers – Fact sheet. 2023. https://www.who.int/health-topics/viral-hemorrhagic-fever#tab=tab_1
2. Centers for Disease Control and Prevention. What is a viral hemorrhagic fever? 2023. https://www.cdc.gov/vhf/whatitis.html
3. Mayo Clinic. Hemorrhagic fevers. 2022. https://www.mayoclinic.org/diseases-conditions/hemorrhagic-fever/symptoms-causes/syc-20354085
4. Cleveland Clinic. Flavivirus infections. 2024. https://my.clevelandclinic.org/health/diseases/22096-flavivirus-infections
5. National Institutes of Health. Favipiravir for emerging viral diseases. 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268239/

```